


Accepted Manuscript

Enhancer of Zeste 1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia

Andrea L. Johnstone, Jiaqi J. O'Reilly, Annika J. Patel, Zhihong Guo, Nadja S. Andrade, Marco Magistri, Lubov Nathanson, Rustam Esanov, Brooke H. Miller, Gustavo Turecki, Shaun P. Brothers, Zane Zeier, Claes Wahlestedt



PII: S0969-9961(18)30419-4
DOI: doi:[10.1016/j.nbd.2018.08.005](https://doi.org/10.1016/j.nbd.2018.08.005)
Reference: YNBDI 4246
To appear in: *Neurobiology of Disease*
Received date: 12 February 2018
Revised date: 7 July 2018
Accepted date: 8 August 2018

Please cite this article as: Andrea L. Johnstone, Jiaqi J. O'Reilly, Annika J. Patel, Zhihong Guo, Nadja S. Andrade, Marco Magistri, Lubov Nathanson, Rustam Esanov, Brooke H. Miller, Gustavo Turecki, Shaun P. Brothers, Zane Zeier, Claes Wahlestedt, Enhancer of Zeste 1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia. *Ynbdi* (2018), doi:[10.1016/j.nbd.2018.08.005](https://doi.org/10.1016/j.nbd.2018.08.005)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Enhancer of Zeste 1 is an antipsychotic-sensitive epigenetic modulator of social and motivational behavior that is dysregulated in schizophrenia

Andrea L. Johnstone^{1,2}, Jiaqi J. O'Reilly^{1,3}, Annika J. Patel¹, Zhihong Guo^{1,4}, Nadja S. Andrade¹, Marco Magistri¹, Lubov Nathanson⁵, Rustam Esanov^{1,6}, Brooke H. Miller⁷, Gustavo Turecki⁸, Shaun P. Brothers¹, Zane Zeier¹, Claes Wahlestedt^{1*}

Author Affiliations:

¹The Center for Therapeutic Innovation and Department of Psychiatry & Behavioral Sciences, University of Miami Miller School of Medicine, Miami, FL; ²EpiCypher, Durham, NC; ³Institute for Biomedical Sciences, George Washington University, Washington, DC; ⁴Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; ⁵Institute for Neuro Immune Medicine, Nova Southeastern University, Fort Lauderdale, FL; ⁶Department of Neuroscience, The Scripps Research Institute, La Jolla, CA; ⁷McKnight Brain Institute and Department of Psychiatry, University of Florida College of Medicine, Gainesville, FL; ⁸Department of Psychiatry, McGill University, Quebec, Canada

***Corresponding Author:**

Claes Wahlestedt, M.D. Ph.D.
Leonard M. Miller Professor;
Director, Center for Therapeutic Innovation;
Associate Dean for Therapeutic Innovation;
Vice Chair for Research
Department of Psychiatry and Behavioral Sciences;
University of Miami Miller School of Medicine
1501 NW 10th Ave * BRB # 407 (M-860)
Miami, FL 33136
Telephone: +1 305 243 7694
Fax: +1 305 243 2523
Cell: +1 561 603 0072
E-mail: cwahlestedt@med.miami.edu

Download English Version:

<https://daneshyari.com/en/article/8686301>

Download Persian Version:

<https://daneshyari.com/article/8686301>

[Daneshyari.com](https://daneshyari.com)